Related Experiment Video

Updated: Apr 10, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Antidiabetic drug effects on gastrointestinal health: convergent evidence from a longitudinal cohort and Mendelian

Xinxuan Li¹, Jie Chen², Lijuan Wang¹

¹Center of Clinical Big Data and Analytics of The Second Affiliated Hospital, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Journal of Advanced Research

|April 8, 2026

Abstract

Introduction:

The global prevalence of diabetes continues to rise, and long-term use of anti-diabetic drugs has thus become a cornerstone of clinical management for most patients.

Objectives:

This study aimed to explore the impact of antidiabetic drug use, combination therapy, and medication sequence on the risk of gastrointestinal disorders.

Methods:

This study included 27,784 type 2 diabetes patients at baseline in the UK Biobank. Multivariate Cox models were employed to explore the associations between antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, alpha glucosidase inhibitors (AGI), glucagon-like peptide-1 receptor agonists (GLP-1RA), and insulin) and the incidence of gastrointestinal disorders. We leveraged the summary statistics from the FinnGen study and genome-wide association studies to perform drug-target Mendelian randomization (MR) analyses, validating the observed associations.

Results:

During a median follow-up period of 15.2 years, sulfonylurea users had a lower risk of colorectal cancer (CRC) (HR: 0.76, 95% CI: 0.62-0.94) than nonsulfonylurea users. Insulin users had a decreased risk of diverticular disease (HR: 0.75, 95% CI: 0.68-0.83) compared with noninsulin users. In addition, metformin combined with sulfonylureas was associated with decreased CRC risk (HR: 0.61, 95% CI: 0.46-0.82), while postmetformin use of DPP-4i with sulfonylureas or GLP-1RA was related to higher acute pancreatitis risk. In two-sample MR, genetically predicted sulfonylureas targeting INS were associated with a reduced risk of CRC (OR: 0.56, 95% CI: 0.35-0.88), and insulin targeting LRP2 was associated with a reduced risk of diverticular disease (OR: 0.89, 95% CI: 0.80-0.98).

Conclusion:

Our study indicates that antidiabetic regimens, including combination therapies and treatment sequences, are clinically important for preventing gastrointestinal morbidity in type 2 diabetes patients. This underscores the need for personalized treatment to prevent gastrointestinal comorbidities.

Keywords:

Antidiabetic drug Combination therapy Gastrointestinal diseases Mendelian randomization Type 2 diabetes

More Related Videos

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Factors Influencing Drug Absorption: Disease States and Pharmacology

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...

Articles linked to this work by shared authors, journal, and citation graph.

Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to GLP1R gene region.

Genetic epidemiology·2024

Genetic investigation into the broad health implications of caffeine: evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization.

BMC medicine·2024

Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study.

Liver international : official journal of the International Association for the Study of the Liver·2024

Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study.

Metabolism: clinical and experimental·2024

Adherence to the Mediterranean diet and nuclear magnetic resonance spectroscopy biomarkers in older individuals at high cardiovascular disease risk: cross-sectional and longitudinal analyses.

The American journal of clinical nutrition·2023

Effective questionnaire-based prediction models for type 2 diabetes across several ethnicities: a model development and validation study.

EClinicalMedicine·2023

See all related articles